Publicação
Private equity investment committee proposal - medpace lbo returns
| Resumo: | Medpace is a CRO company focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharma and medical-device industries. Its strong positioning in a niche market, the high projected industry growth, its strong and stable FCFs, and experienced management team make it an ideal target, which would be further improved by our developed business plan that will enhance its operations, expand internationally, and capitalize on M&A trends. The business plan is expected to deliver high returns, translating into a money multiple of 3.28x and an IRR of 26.84%, which are further analysed in the individual part of this paper. |
|---|---|
| Autores principais: | Pérez, Mafalda Pinto De Sousa Von Hafe |
| Assunto: | Contract research organization (Cro) Research & development (R&D) Mergers & acquisitions (M&A) Biopharma Leverage buyout (Lbo) Money multiple (Mm) Internal rate of return (Irr) Private equity (Pe) |
| Ano: | 2023 |
| País: | Portugal |
| Tipo de documento: | dissertação de mestrado |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Universidade Nova de Lisboa |
| Idioma: | inglês |
| Origem: | Repositório Institucional da UNL |
| Resumo: | Medpace is a CRO company focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharma and medical-device industries. Its strong positioning in a niche market, the high projected industry growth, its strong and stable FCFs, and experienced management team make it an ideal target, which would be further improved by our developed business plan that will enhance its operations, expand internationally, and capitalize on M&A trends. The business plan is expected to deliver high returns, translating into a money multiple of 3.28x and an IRR of 26.84%, which are further analysed in the individual part of this paper. |
|---|